Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro

doi:10.1056/nejmoa0909530

Public

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Published in New England Journal of Medicine • Jun 23, 2010

Authors:

Makoto Maemondo

Akira Inoue

Kunihiko Kobayashi

Abstract

BACKGROUND: Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of standard chemotherapy. METHODS...

Subject

Gefitinib

Medicine

Lung cancer

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!